These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

993 related articles for article (PubMed ID: 1415443)

  • 1. The metabolic impact of oral contraceptives.
    Krauss RM; Burkman RT
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1177-84. PubMed ID: 1415443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
    Crook D; Godsland IF; Wynn V
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
    Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
    J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
    Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
    Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A norgestimate-containing oral contraceptive: review of clinical studies.
    Kafrissen ME
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of triphasic levonorgestrel in oral contraception: a review of metabolic and hemostatic effects.
    Lachnit-Fixson U
    Gynecol Endocrinol; 1996 Jun; 10(3):207-18. PubMed ID: 8862497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipids, cardiovascular disease, and oral contraceptives: a practical perspective.
    Upton GV
    Fertil Steril; 1990 Jan; 53(1):1-12. PubMed ID: 2403935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
    Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipids and cardiovascular disease: do the findings and therapy apply equally to men and women?
    LaRosa JC
    Womens Health Issues; 1992; 2(2):102-11; discussion 111-3. PubMed ID: 1617306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lipids, lipoproteins, arterial accidents and oral contraceptives].
    Bakir R; Hilliquin P
    Contracept Fertil Sex (Paris); 1986 Jan; 14(1):81-7. PubMed ID: 12341243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of estrogens and progestogens on lipid metabolism.
    Oster P; Arab L; Kohlmeier M; Mordasini R; Schellenberg B; Schlierf G
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):773-5. PubMed ID: 7065057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metabolic risks of oral contraception].
    Monier L
    Rev Int Pediatr; 1988 Feb; (178):64-5. PubMed ID: 12282576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contraception for women with diabetes: an update.
    Skouby SO; Mølsted-Pedersen L; Petersen KR
    Baillieres Clin Obstet Gynaecol; 1991 Jun; 5(2):493-503. PubMed ID: 1954724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of progestins in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins.
    Wynn V; Niththyananthan R
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):766-71. PubMed ID: 6801982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives.
    Spellacy WN
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):732-4. PubMed ID: 7039318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives.
    Oyelola OO
    Contraception; 1993 May; 47(5):445-54. PubMed ID: 8513671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease.
    Gaspard UJ; Lefebvre PJ
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):334-43. PubMed ID: 2196805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.